US President Donald Trump makes an announcement in the Oval Office of the White House in…
Category: News
2026 Star Ratings: What they mean and what comes next
With the Centers for Medicare & Medicaid Services (CMS) publishing the 2026 Star Ratings earlier this…
Nanoscope Therapeutics President and Chief Scientific Officer Dr. Samarendra Mohanty to Be Featured Speaker at 2025 ISPE Annual Meeting and Expo
A sign is posted in front of a Genentech office on June 12, 2025 in South…
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration…
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Dario Amodei, Anthropic CEO,speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland…
Integral Consulting and Verdi Technology Form Strategic Partnership to Advance Occupational Health, Safety, and Chemical Risk Management Solutions for EV and Lithium-Battery Value Chain
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic…
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader…
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability
SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ — The highly anticipated 2025IDF World Dairy Summit took place…
Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic
Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ –Alphyn,…
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both…